Various embodiments disclosed relate to an antifungal-grafted polyolefin. The present invention provides an antifungal-grafted polyolefin comprising an antifungal-grafted repeating unit having the structure:

##STR00001##

At each occurrence, -A- can be chosen from —O— and —NH—. At each occurrence, -AF can be an independently selected grafted antifungal compound. At each occurrence, -L- can be independently chosen from a bond and the structure:

##STR00002##

or a salt thereof.
At each occurrence —R can be independently chosen from —H and -AF. At each occurrence, the variable n is independently about 1 to about 100,000.

The present invention relates to methods for making wear and oxidation resistant polymeric materials by high temperature melting. The invention also provides methods of making medical implants containing cross-linked antioxidant-containing tough and ductile polymers and materials used therewith also are provided.

The present invention relates to methods for making wear and oxidation resistant polymeric materials by high temperature melting. The invention also provides methods of making medical implants containing cross-linked antioxidant-containing tough and ductile polymers and materials used therewith also are provided.

The subject invention provides devices and methods for alleviating discomfort associated with neuroma formation. The devices and methods of the invention effectively use the body's natural response of reconstructing implanted biomaterials to minimize the size of, isolate, and protect a neuroma. In preferred embodiments, the subject device is a cylindrical cap, wherein the internal chamber of the cylindrical cap physically partitions the nerve to enable an arrangement of nerve fibers (as opposed to haphazardly arranged nerve fibers often produced in neuromas). Tabs arranged on the outside of the cap can be used to manipulate the cap into place on a nerve. The open end can also be configured with flaps that can be used to widen the open end for easier insertion of the nerve into the cap. In addition, the cap's material remodels into a tissue cushion after implantation, which protects the neuroma from being stimulated and inducing pain.

The subject invention provides devices and methods for alleviating discomfort associated with neuroma formation. The devices and methods of the invention effectively use the body's natural response of reconstructing implanted biomaterials to minimize the size of, isolate, and protect a neuroma. In preferred embodiments, the subject device is a cylindrical cap, wherein the internal chamber of the cylindrical cap physically partitions the nerve to enable an arrangement of nerve fibers (as opposed to haphazardly arranged nerve fibers often produced in neuromas). Tabs arranged on the outside of the cap can be used to manipulate the cap into place on a nerve. The open end can also be configured with flaps that can be used to widen the open end for easier insertion of the nerve into the cap. In addition, the cap's material remodels into a tissue cushion after implantation, which protects the neuroma from being stimulated and inducing pain.

Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices. The devices may be comprised of novel expansile materials, novel infrastructure design, or both. The devices provided are very flexible and enable deployment with reduced or no damage to bodily tissues, conduits, cavities, etceteras.

A method for fabricating an embodiment of a medical device comprising the steps of: preparing a biodegradable polymeric structure; coating the biodegradable polymeric structure with a polymeric coat including a pharmacological or biological agent; cutting the structure into patterns configured to allow for crimping of the cut structure and expansion of the cut structure after crimping into a deployed configuration.

A cerebral spinal fluid shunt plug includes a shunt plug housing having a shunt valve recess formed therein and a window recess with an access hole. The cerebral spinal fluid shunt plug also includes a shunt valve shaped and dimensioned for positioning within the shunt valve recess of the shunt plug housing and a lucent disk shaped and dimensioned for the passage through the central access hole of the shunt plug housing. In another embodiment, a cerebral spinal fluid shunt plug includes a shunt plug housing having a shunt valve recess formed therein and an intracranial monitoring device recess with an access hole. A shunt valve is positioned within the shunt valve recess of the shunt plug housing and an intracranial monitoring device is passed through the central access hole of the shunt plug housing.

A cerebral spinal fluid shunt plug includes a shunt plug housing having a shunt valve recess formed therein and a window recess with an access hole. The cerebral spinal fluid shunt plug also includes a shunt valve shaped and dimensioned for positioning within the shunt valve recess of the shunt plug housing and a lucent disk shaped and dimensioned for the passage through the central access hole of the shunt plug housing. In another embodiment, a cerebral spinal fluid shunt plug includes a shunt plug housing having a shunt valve recess formed therein and an intracranial monitoring device recess with an access hole. A shunt valve is positioned within the shunt valve recess of the shunt plug housing and an intracranial monitoring device is passed through the central access hole of the shunt plug housing.

A propylene copolymer composition comprising A) a propylene butylene copolymer which is—free of phthalicacid esters as well as decomposition products thereof; —obtained by a Ziegler-Natta catalyst and B) at least one α-nucleating agent, the propylene copolymer composition having—a MFR (2.16 kg/210° C.) in the range of 2 to 100 g/10 min—a melting point Tm(1) of less than 140° C.—a melting point Tm(2) of at least 150° C., said Tm(2) being associated with more than 75% of the total melting enthalpy and whereby the propylene copolymer—has monomer units derived from a) propylene in an amount of 90.0-98.0 mol.-% b) butylene in an amount of 2.0-10.0 mol.-% with respect to the total weight of the propylene butylene copolymer—an isotacticity mm % as determined by .sup.13C NMR spectroscopy of below 99.0%; and—a Koenig-B parameter with respect to butylene as determined by .sup.13C NMR spectroscopy of more than 0.98.